Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1Integrase Inhibitor
GSK3839919A is a potent allosteric inhibitor of HIV-1 integrase, targeting the enzyme responsible for the integration of viral DNA into the host genome. This compound exhibits significant antiviral activity against HIV-1, making it a valuable tool for research applications focused on the development of novel antiretroviral therapies and the study of HIV replication mechanisms. Its unique mechanism of action may provide insights into resistance pathways and inform drug design strategies. -
HIV Integrase Inhibitor
His-Cys-Lys-Phe-Trp-Trp is an HIV integrase inhibitor, exhibiting an IC50 of 2 μM. This compound impedes the integrase enzyme's function, thereby preventing viral DNA integration into the host genome. His-Cys-Lys-Phe-Trp-Trp is valuable for research focused on HIV pathogenesis and the development of antiretroviral therapies. -
HIV-1 integrase Inhibitor
(S)-BI-1001 is a potent HIV-1 integrase inhibitor, demonstrating significant antiviral activity. It exhibits an IC50 value of 28 nM, an EC50 of 450 nM, and a Kd of 4.7 μM, indicating its efficacy in disrupting viral replication processes. This compound is valuable for research applications focused on HIV-1 pathogenesis and therapeutic development. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 7 is a potent inhibitor of HIV-1 integrase, exhibiting an IC50 value of 33.3 nM. This compound effectively interferes with the integration of viral DNA into the host genome, making it essential for studies focused on HIV-1 replication and treatment strategies. It serves as a valuable tool in research applications aimed at understanding HIV-1 biology and developing therapeutic interventions against HIV. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 11 is a potent inhibitor of HIV-1 integrase, demonstrating an IC50 of 125 μM. This compound effectively disrupts the integration of viral DNA into the host genome, thereby hindering the replication process of HIV-1. It is suitable for research applications aimed at developing antiretroviral therapies and studying the mechanisms of HIV integration and resistance. -
HIV-1 IN/RT RNase H Inhibitor
2-Hydroxyisoquinoline-1,3(2H,4H)-dione is an inhibitor of HIV-1 integrase (IN) and reverse transcriptase (RT) ribonuclease H (RNase H), demonstrating IC50 values of 6.32 µM and 5.9 µM, respectively. This compound serves as a valuable tool for studying HIV-1 replication and provides insights into the inhibition mechanisms of viral enzymes. Its biological activity and specificity make it useful for research applications focused on antiviral drug development and understanding HIV-1 pathogenesis. -
HIV Integrase Inhibitor
L-870812 is an HIV integrase inhibitor that targets the strand transfer mechanism of HIV-1 integration. This compound effectively blocks both cell-free and cell-associated HIV-1 infections, demonstrating activity against subtype C and CRFO2_AG primary isolates. L-870812 is suitable for research applications involving replication-deficient HIV-1 Ba-L (env) pseudovirus, facilitating studies aimed at understanding HIV biology and developing therapeutic strategies. -
HIV protease inhibitor
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. -
HIV reverse transcriptase inhibitor
Dapivirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) -
HIV-1 RT inhibitor
Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate. -
HIV Entry Inhibitor
BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. -
HIV-1 integrase inhibitor
HIV-1 integrase inhibitor is uesful for anti-HIV. -
HIV-1 integrase inhibitor
HIV-1 integrase inhibitor 2, in the treatment of human immunodeficiency virus (HIV) infection. -
HIV Protease Inhibitor
Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy. -
HIV protease inhibitor
Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. -
HIV Integrase Inhibitor
GSK1265744 (GSK744) is a potential inhibitor of HIV integrase with IC50 value of 3 nM -
HIV-1 attachment inhibitor
BMS-626529 is a potent HIV-1 attachment inhibitor. BMS-663068 is also the phosphonooxymethyl prodrug of BMS-626529 that targets HIV-1 gp120 and prevents its binding to CD4(+) T cells. -
HIV protease inhibitor
Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. -
HIV-1 maturation inhibitor
GSK3532795, also known as BMS-955176, is a potent, orally active, second-generation HIV-1 maturation inhibitor. CAS: 1392312-45-6 (free base) 2023808-13-9 (HCl) 2023798-97-0 (HCl hydrate) 2097784-79-5 (oxalate) -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV fusion inhibitor
Enfuvirtide Acetate (T-20) is a 36 amino acid peptide corresponding to a region of gp41, the transmembrane subunit of HIV-1 envelope protein. -
HIV maturation inhibitor
GSK2838232-isomer is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection.
-
HIV integrase inhibitor
GSK744 is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. -
HIV integrase inhibitor
Dolutegravir sodium is a HIV integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. -
HIV-1 capsid CTD dimerization inhibitor
Ebselen (SPI-1005) is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen can permeate the blood-brain barrier and inhibit inositol monophosphatase (IMPase). Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties. Ebselen inhibits QSOX1 enzymatic activity and has anticancer activity . -
HIV-1 reverse transcriptase inhibitor
beta-L-D4A is a nucleoside HIV-1 reverse transcriptase inhibitor. -
HIV capsid inhibitor
CA inhibitor 1 (GS-6207 analog) is a potent HIV capsid inhibitor for HIV inhibition. -
HIV infection inhibitor
HIV-1 inhibitor-3 is a HIV infection inhibitor extracted from patent US2018360927. -
HIV-1 attachment inhibitor
BMS-663068 tris is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection. -
HIV protease inhibitor
Fosamprenavir Calcium Salt is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir, with improved solubility over the parent molecule and a potential for reduced pill burden on current dosing regimens; GW433908G is the calcium salt of the prodrug. -
HIV protease inhibitor
Tipranavir, a nonpeptidic HIV protease inhibitor (NPPI), inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates. -
HIV Protease Inhibitor
Indinavir is a selective inhibitor of HIV-1 protease, displaying a Ki value of 0.54 nM, making it a potent antiviral agent. In addition to its primary role in HIV treatment, Indinavir has demonstrated anticancer properties by inhibiting matrix metalloproteinases (MMPs) and promoting anti-angiogenic effects, alongside inducing apoptosis in cancer cells. Furthermore, Indinavir has shown inhibitory activity against the SARS-CoV 3CL protease, expanding its potential applications in viral research. -
HIV Integrase Inhibitor
Equisetin is an N-methylserine-derived acyl tetramic acid that functions as a potent HIV integrase inhibitor. It specifically interferes with the activity of HIV-1 integrase and demonstrates notable inhibition of 11β-HSD1 and Dnp-stimulated ATPase, with an IC50 of approximately 8 nmol per mg of protein. Additionally, Equisetin exhibits significant antibacterial properties, anti-inflammatory effects, and potential benefits in managing lipid-associated disorders while also showcasing cytotoxic activity. This compound is valuable for research applications focused on HIV treatment and the exploration of antimicrobial and anti-inflammatory mechanisms. -
HIV Protease Inhibitor
Indinavir sulfate ethanolate is a selective inhibitor of HIV-1 protease, demonstrating a potent Ki of 0.54 nM for the target enzyme. Beyond its antiviral activity, this compound has shown potential in anticancer research through the inhibition of MMPs-2 activation, anti-angiogenic effects, and promotion of apoptosis. Additionally, Indinavir sulfate ethanolate acts as an inhibitor of the SARS-CoV 3CLpro enzyme, highlighting its diverse biological activity and relevance in multiple research applications. -
HIV-1 RT Inhibitor
Apricitabine is a selective inhibitor of HIV-1 reverse transcriptase (RT) with a Ki value of 0.08 μM. It also exerts inhibitory effects on DNA polymerases α, β, and γ, with corresponding Ki values of 300 μM, 12 μM, and 112.25 μM. Demonstrating significant antiretroviral efficacy and favorable tolerability, Apricitabine shows a reduced potential for resistance development in patients with antiretroviral-naive HIV infection. This compound is applicable for research in the mechanisms of HIV-1 replication and antiviral drug development. -
DNA Synthesis/HSV/HIV-1 Inhibitor
16,16-Dimethyl prostaglandin A1 is a prostaglandin analog that primarily inhibits DNA synthesis. It demonstrates significant antiviral activity by reducing viral replication in both herpes simplex virus (HSV) and HIV-1 infection models. This compound serves as a valuable tool for research focused on cancer biology and viral pathogenesis. -
HIV-1 Reverse Transcriptase Inhibitor
R82913 (9-Cl-TIBO) is a selective inhibitor of HIV-1 reverse transcriptase, demonstrating significant antiviral activity against both RNA and DNA templates crucial for viral replication. This compound effectively inhibits the replication of various HIV-1 strains in CEM cells, with a median IC50 value of 0.15 μM. It serves as a valuable reagent for research applications focused on HIV therapy development and reverse transcriptase inhibition studies. -
HIV Inhibitor
Fozivudine tidoxil is an orally active HIV inhibitor designed as a thioether lipid-zidovudine (ZDV) conjugate. This compound exhibits potent anti-HIV activity by incorporating into the newly synthesized DNA strand during viral replication, leading to irreversible binding to viral reverse transcriptase and disruption of the reverse transcription process. In addition to its antiviral properties, Fozivudine tidoxil is also a versatile click chemistry reagent, capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with suitable alkyne or DBCO/BCN-containing molecules, making it valuable for chemical biology applications. -
HIV-1 Inhibitor
HIV-1 Inhibitor-43 is a selective inhibitor targeting the HIV-1 virus. It demonstrates potent efficacy with an EC50 of 21.3 nM for Y188L mutants, 6.2 nM for K103N-Y181C, and under 0.7 nM for both K103N and Y181C strains. This compound effectively reduces HIV-1 RNA levels and protein p24 expression, making it a valuable tool for research in HIV pathogenesis and therapeutic development. -
DENV/HIV-1 Inhibitor
DENV-IN-5 is a potent inhibitor targeting both dengue virus (DENV) and HIV-1 replication. It demonstrates effective antiviral activity with half-maximal effective concentration (EC50) values of 1.47, 9.23, 7.08, and 8.91 μM against DENV serotypes I to IV, respectively. Additionally, DENV-IN-5 inhibits the HIV-1 IIIB strain with an EC50 of 0.1512 μM. This compound is valuable for research focused on viral infections and the development of antiviral therapies.
